0000899243-20-015413.txt : 20200605 0000899243-20-015413.hdr.sgml : 20200605 20200605160603 ACCESSION NUMBER: 0000899243-20-015413 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200603 FILED AS OF DATE: 20200605 DATE AS OF CHANGE: 20200605 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fox Jonathan C CENTRAL INDEX KEY: 0001655016 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38533 FILM NUMBER: 20946160 MAIL ADDRESS: STREET 1: C/O MYOKARDIA, INC. STREET 2: 333 ALLERTON AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Eidos Therapeutics, Inc. CENTRAL INDEX KEY: 0001731831 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463733671 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 650-391-9740 MAIL ADDRESS: STREET 1: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-03 0 0001731831 Eidos Therapeutics, Inc. EIDX 0001655016 Fox Jonathan C C/O EIDOS THERAPEUTICS, INC. 101 MONTGOMERY STREET, SUITE 2000 SAN FRANCISCO CA 94104 0 1 0 0 See Remarks Common Stock 2020-05-31 5 A 0 E 444 41.5735 A 3294 D Common Stock 2020-06-01 5 G 0 E 1020 0.00 D 397605 I See footnote Common Stock 2020-06-02 5 G 0 E 1020 0.00 D 396585 I See footnote Common Stock 2020-06-03 4 S 0 5000 50.00 D 391585 I See footnote Shares acquired pursuant to the Issuer's 2018 Employee Stock Purchase Plan. The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2020. President and Chief Medical Officer /s/ Franco Valle, as Attorney-in-Fact 2020-06-05